CVB homepage

Immediate Past President of the American College of Cardiology (ACC) Hadley Wilson, MD, FACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute and a clinical professor of medicine at Wake Forest University School of Medicine, details the top late-breaking studies at AHA 2024. #AHA24 #AHA2024

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Redo TAVR: A 26-mm Sapien 3 device (Edwards Lifesciences) implanted within a 29-mm CoreValve device (Medtronic). Image courtesy of EuroIntervention.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

heart drugs with stethoscope

The popular DOAC was linked to more bleeding events than warfarin, but fewer reports of intracardiac thrombi and other adverse outcomes. Researchers presented their findings at the AHA's Scientific Sessions 2024 conference in Chicago.

Deep learning recons reduce contrast and radiation doses in aortic CTA

A new analysis in Academic Radiology dives into the importance of finding balance between reducing radiation exposure while maintaining image quality. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."